Candesartan

As a chronic cardiovascular disease affecting more than 1.2 billion people worldwide, hypertension is clinically treated with angiotensin II receptor antagonists (ARBs) as first-line antihypertensive drugs at present. Candesartan is a representative variety among them with long duration of action and good tolerability. It blocks the type 1 receptor of angiotensin II with high selectivity, inhibits vasoconstriction and aldosterone release, steadily lowers blood pressure, and simultaneously reduces the risk of cardiovascular events and delays the progression of diabetic nephropathy. In addition to patients with essential hypertension, it is also applicable to specific populations with comorbid left ventricular hypertrophy and chronic renal insufficiency.

At present, the global market size of candesartan is approximately USD 1.2 billion. Driven by the rising prevalence of chronic diseases and the demand for improvement in the hypertension control rate, the compound annual growth rate in the past three years has maintained at around 2.8%. The market size in China is approximately RMB 1.8 billion. After the implementation of centralized drug procurement, the substitution rate of generic drugs has exceeded 92%, the overall market pattern is stable, the demand side of active pharmaceutical ingredients shows obvious rigid characteristics, and no new target-equivalent competitive products have posed an obvious substitution threat.

The original developer of candesartan is Takeda Pharmaceutical of Japan, with the original brand name "Blopress". The core compound patent expired globally in 2011. The main dosage form approved for the original product is tablet, with conventional specifications including 4mg, 8mg and 16mg. It has been included in the *Catalogue of Reference Preparations of Chemical Drugs* of China, and is also listed in the FDA Reference Preparations Catalogue. At present, candesartan active pharmaceutical ingredients from more than 20 enterprises in China have obtained Class A status through CDE registration, and the corresponding approved preparation varieties cover multiple dosage forms such as candesartan cilexetil tablets and candesartan cilexetil capsules. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO provides a full series of candesartan impurity reference standards. Most products are available from stock, and orders placed before 16:00 can be shipped on the same day. All products meet the requirements of multiple national regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the reference standard use needs of pharmaceutical enterprises in the whole process from API R&D to quality control.